Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Patients Less Than 1 Year of Age

NCT04188964 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

X-linked Hypophosphatemia (XLH)

Interventions

DRUG: Burosumab

Sponsor

Kyowa Kirin Pharmaceutical Development Ltd